NCT04167137: Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Subjects

NCT04167137
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older ¬† (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with clinically active unstable central nervous system (CNS) metastases and/or carcinomatous meningitis – see trial for details
https://ClinicalTrials.gov/show/NCT04167137

Comments are closed.

Up ↑